Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs

All NewsMarch 19, 2026

Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes against weak data signals.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent